benzyl 4-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-4-oxobutanoate | 170935-70-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: benzyl 4-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-4-oxobutanoate
• CAS: 170935-70-3
• 化学式: C₂₀H₂₃N₃O₈
• 分子量: 433.418
• InChiKey: RQHJQOBVOIVJDQ-CODKJTEISA-N

物化性质

• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  158
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  benzyl 4-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-4-oxobutanoate 在 porcine liver esterase phosphate buffer 、 水 作用下， 以 乙醇 为溶剂， 生成 阿糖胞苷
  参考文献：
  名称：

  Kawaguchi; Youssef; Aboul-Fadl, Pharmazie, 1996, vol. 51, # 10, p. 717 - 719

  摘要：

  DOI：
• 作为产物：
  描述：

  succinic acid benzyl ester 2,3,4,5,6-pentafluorophenyl ester 、 阿糖胞苷 以 N,N-二甲基甲酰胺 为溶剂， 生成 benzyl 4-[[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]amino]-4-oxobutanoate
  参考文献：
  名称：

  Synthesis and Reactivity of 5-Fluorouracil/Cytarabine Mutual Prodrugs

  摘要：

  Two mutual prodrugs, in which two different anti-cancer drugs are attached to the same molecule via labile linkages, are synthesized and examined kinetically. One of the mutual prodrugs loses a drug component under physiological conditions within an hour, but the other mutual prodrug (having a longer spacer between the two drugs) is stable to chemical degradation even at higher pH values. Thus, enzymatic hydrolysis alone will release the two anti-cancer drugs. The potential value of anti-cancer mutual prodrugs is discussed.

  DOI：

  10.1021/jo971076p

文献信息

• Fadl; Hasegawa; Youssef, Pharmazie, 1995, vol. 50, # 6, p. 382 - 387
  作者：Fadl、Hasegawa、Youssef、Farag、Omar、Kawaguchi

  DOI：——

  日期：——
• Synthesis and Reactivity of 5-Fluorouracil/Cytarabine Mutual Prodrugs
  作者：Fredric M. Menger、Michael J. Rourk

  DOI：10.1021/jo971076p

  日期：1997.12.1

  Two mutual prodrugs, in which two different anti-cancer drugs are attached to the same molecule via labile linkages, are synthesized and examined kinetically. One of the mutual prodrugs loses a drug component under physiological conditions within an hour, but the other mutual prodrug (having a longer spacer between the two drugs) is stable to chemical degradation even at higher pH values. Thus, enzymatic hydrolysis alone will release the two anti-cancer drugs. The potential value of anti-cancer mutual prodrugs is discussed.
• Kawaguchi; Youssef; Aboul-Fadl, Pharmazie, 1996, vol. 51, # 10, p. 717 - 719
  作者：Kawaguchi、Youssef、Aboul-Fadl、Omar、Farag、Hasegawa

  DOI：——

  日期：——